About Hemay
Hemay was established in 2002 and is based in Tianjin, China. Operations are centered on the production of pharmaceutical drugs across various therapeutic areas within the healthcare sector. Manufacturing processes are conducted to develop medications for diverse medical needs. The companys domain, hemay.com.cn, supports its activities in drug formulation and distribution. Focus remains on standard pharmaceutical practices in the region.
- Headquarter Tianjin, China
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
Hongfu Assets
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Hemay
Investors in Hemay
Hemay has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Hongfu Assets, Jihan Investment and Taikun Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Hemay
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Hemay
Investment portfolio details for Hemay
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Hemay
Detailed financials for Hemay
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Hemay Comparisons
Peer comparison for Hemay
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Hemay
Detailed competitors of Hemay
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Hemay
Complete news archive for Hemay
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Hemay
Hemay was founded in 2002 and raised its 1st funding round 21 years after it was founded.
Hemay is headquartered in Tianjin, China.
Hemay was established in 2002 and is based in Tianjin, China. Operations are centered on the production of pharmaceutical drugs across various therapeutic areas within the healthcare sector. Manufacturing processes are conducted to develop medications for diverse medical needs. The companys domain, hemay.com.cn, supports its activities in drug formulation and distribution. Focus remains on standard pharmaceutical practices in the region.
Hemay has 5 investors. Key investors include Hongfu Assets, Jihan Investment, Taikun Investment, Anxin Guosheng Microchip, and Development Control Investment.